Sachio Shibata

Fujisawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Identification of the first highly selective inhibitor of human lactate dehydrogenase B.

Identification of the first highly selective inhibitor of human lactate dehydrogenase B.

Journal: Scientific reports

Published: July 16, 2021

A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.

A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.

Journal: Journal of neurochemistry

Published: April 14, 2021

Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension.

Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension.

Journal: Bioscience, biotechnology, and biochemistry

Published: March 06, 2019

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.

Journal: Science advances

Published: September 10, 2018

Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents.

Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents.

Journal: Bioorganic & medicinal chemistry

Published: December 26, 2017

Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.

Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 13, 2017

CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

Journal: Scientific reports

Published: June 19, 2017

Antitumor activity of a novel and orally available inhibitor of serine palmitoyltransferase.

Antitumor activity of a novel and orally available inhibitor of serine palmitoyltransferase.

Journal: Biochemical and biophysical research communications

Published: December 26, 2016

Synthesis and evaluation of hedgehog signaling inhibitor with novel core system.

Synthesis and evaluation of hedgehog signaling inhibitor with novel core system.

Journal: Bioorganic & medicinal chemistry

Published: April 01, 2015

Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.

Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: January 10, 2013

Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors.

Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: May 25, 2012

Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility.

Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility.

Journal: Bioorganic & medicinal chemistry

Published: May 25, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026